Clearmind Medicine Inc. Common Shares
CMND50
$1.33arrow_drop_down0.02%-$0.00
Penny Stock
CMND50
$1.33
arrow_drop_down0.02%Performance History
| Key Stats | |
|---|---|
| Open | $1.33 |
| Prev. Close | $1.32 |
| EPS | 7.87 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $5.34M |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.31 | 1.36 |
| 52 Week Range | 0.10 | 12.33 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | 7.87 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Clearmind Medicine Inc. Common Shares (CMND)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Headquarters
- Vancouver
- Employees
- 0
- Exchange
- NASDAQ
Keep an eye on Clearmind Medicine Inc. Common Shares
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is the market capitalization of Clearmind Medicine Inc. Common Shares (CMND)?
Clearmind Medicine Inc. Common Shares (CMND) has a market capitalization of $5.34M. The average daily trading volume is 71K, indicating the stock's liquidity and investor engagement.
help
What is Clearmind Medicine Inc. Common Shares's (CMND) price per share?
The current price per share for Clearmind Medicine Inc. Common Shares (CMND) is $1.3. The stock has seen a price change of -$0 recently, indicating a -0.03% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Clearmind Medicine Inc. Common Shares (CMND)?
For Clearmind Medicine Inc. Common Shares (CMND), the 52-week high is $10.35, which is 672.62% from the current price. The 52-week low is $0.11, the current price is 1.13K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Clearmind Medicine Inc. Common Shares (CMND) a growth stock?
Clearmind Medicine Inc. Common Shares (CMND) has shown an average price growth of 0.41% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Clearmind Medicine Inc. Common Shares as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Clearmind Medicine Inc. Common Shares (CMND) stock price performance year to date (YTD)?
As of the latest data, Clearmind Medicine Inc. Common Shares (CMND) has a year-to-date price change of -51.81%. Over the past month, the stock has experienced a price change of 17.51%. Over the last three months, the change has been 20.68%. Over the past six months, the figure is 5.48%.
help
Is Clearmind Medicine Inc. Common Shares (CMND) a profitable company?
Clearmind Medicine Inc. Common Shares (CMND) has a net income of -$8.62M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$8.5M. Furthermore, the EBITDA is -$5.48M.
News
SCISPARC
CLEARMIND MEDICINE
MEAI
WEIGHT LOSS
OBESITY
METABOLIC SYNDROME
8/6/2024SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SCISPARC
CLEARMIND MEDICINE
PATENT APPLICATION
PEA
MEAI
METABOLIC SYNDROME
OBESITY
OBESITY TREATMENT MARKET
7/16/2024SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - GlobeNewswire
PRESS RELEASES
HEALTH
PATENTS
6/28/2024Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
PRESS RELEASES
COMPANY ANNOUNCEMENT
6/20/2024Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
PRESS RELEASES
PRODUCT / SERVICES ANNOUNCEMENT
CLINICAL STUDY
6/11/2024Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
PRESS RELEASES
PATENTS
5/10/2024Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product